A subset of cell clusters with malignant features in morphologically normal-appearing and hyperplastic tissues

Cancer Detection and Prevention

Volumn 30, Issue 3, 2006, Pages 239-247

  Man, Yan gao ^a   Nieburgs, Herbert E ^b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Beta protein1; Breast tumor progression and invasion; Buccal cells; c erb B2; Cytology; Ductal carcinoma in situ; Estrogen receptor; Estrogen receptor negative cell clusters; Immunohistochemistry; Malignancy associated biomarkers; Malignancy associated changes (MAC); Myeloepithelial cells; Nuclear changes; p53; Prognosis; Smooth muscle actin

Indexed keywords

BIOLOGICAL MARKER; DNA; ESTROGEN RECEPTOR; RNA;

ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; BREAST TUMOR; CANCER INVASION; CANCER SUSCEPTIBILITY; CELL INVASION; CELL POLARITY; CELL SHAPE; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DNA STRUCTURE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH;

ACTINS; BREAST; BREAST NEOPLASMS; CELL NUCLEUS; CYTOLOGICAL TECHNIQUES; CYTOPLASM; DNA; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746751425     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.04.006     Document Type: Article

References (50)

1. Beckmann M.W., Niederacher D., Schurch H.G., Gusterson B.A., and Bender H.G. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75 (1997) 429-439
2. Boyd J.A., and Barrett J.C. Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther 46 (1990) 469-486
3. Schedin P., and Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res 6 (2004) 93-101
4. Pitot H.C. Multistage carcinogenesis-genetic and epigenetic mechanisms in relation to cancer prevention. Cancer Detect Prev 17 (1993) 567-573
5. Page D.L., Jensen R.A., and Simpson J.F. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol 11 (1998) 120-128
6. Singletary S.E., Allred C., Ashley P., Basett L.W., Berry D., and Bland K.I. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83 (2003) 803-819
7. Lakhani S.R., Gusterson B.A., Jacquemier J., Sloane J.P., Anderson T.J., and van de Vijver M.J. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6 (2000) 782-789
8. Jensen R.A., and Page D.L. Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions. Am J Surg Pathol 27 (2003) 828-831
9. Hadjisavvas A., Mikellidou C., Zenios A., Zouvani I., Admou A., and Christodoulou C. Correlation between morphology, immunohistochemistry and molecular pathology in hereditary and sporadic breast cancer cases. Ultrastruct Pathol 26 (2002) 237-244
10. Azzopardi J.G. Problem in breast pathology (1979), W.B. Saunders, London p. 192-210
11. Moinfar F., Man Y.G., Bratthauer G.L., Ratschek M., and Tavassoli F.A. Genetic abnormalities in mammary ductal intraepithelial neoplasis-flat-type ("clinging ductal carcinoma in situ"). A simulator of normal mammary epithelium. Cancer 88 (2000) 2072-2081
12. Nieburgs H.E. Cell morphology in the field effects and in sites distant from malignant tumors. Cancer Detect Prev 28 (2004) S181
13. Nieburgs H.E., Parets A.D., Perez V., and Bouderau C. Cellular changes in liver tissue adjacent and distant to malignant tumors. Arch Pathol 80 (1965) 262-272
14. Nieburgs H.E., Reisman H., and Pacheco B. Interpretation of cellular changes preceding invasive uterine cervix carcinoma. Cancer 16 (1963) 480-501
15. Nieburgs H.E., Herman B.E., and Reisman H. Buccal cell changes in patients with malignant tumors. Lab Invest 11 (1962) 80-88
16. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Rejther A., and Kavarik J. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46 (1990) 839-844
17. Moll U.M., Riou G., and Levine A.J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89 (1992) 7262-7266
18. Man Y.G., Fu S.W., Schwartz A., Pingone J.J., Simmens S.J., and Berg P.E. Expression of BP1, a novel homeotic gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat 90 (2005) 241-247
19. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., and Keith D.E. Studies of the Her-2/new proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
20. Man Y.G., Tai L., Barner R., Vang R., Saenger J.S., Shekitka K.M., et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 5 (2003) R231-R241
21. Man Y.G., and Sang Q.X.A. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Exp Cell Res 301 (2004) 103-118
22. Man Y.G., Zhang Y., Shen T., Vinh T.N., Zeng X., Tauler J., et al. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat 89 (2005) 199-208
23. Niederacher D., Schnurch H.G., An H.X., Ellenberger I., Dall P., and van Roeyen C.R. Detection of sequential genetic alterations relevant for breast cancer development. Eur J Cancer 5 (1996) 497-503
24. Barrett J.C. Mechanism of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100 (1993) 9-20
25. Mayer P., and Hollt V. Genetic disposition to addictive disorders-current knowledge and future perspectives. Curr Opin Pharmacol 5 (2005) 4-8
26. Nowell P.C. The clonal evolution of tumor cell populations. Science 94 4260 (1976) 23-28
27. Tavassoli F.A., and Man Y.G. Morphofunctional features of intraductal hyperplasia, atypical hyperplasia, and various grades of intraductal carcinoma. Breast J 1 3 (1995) 155-162
28. Man Y.G., and Burgar A. An antigen unmasking protocol that satisfies both immunohistochemical and subsequent molecular biological assessments. Pathol Res Pract 199 (2003) 815-825
29. Man Y.G., and Tavassoli F.A. A simple epitope retrieval method without the use of microwave oven or enzyme digestion. Appl Immunohistochem 4 2 (1996) 139-141
30. Handschuh G., Candidus S., Luber B., Reich U., Schott C., and Oswald S. Tumor-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 8 (1999) 4301-4312
31. Luber B., Candidus S., Handschuh G., Mentele E., Hutzler P., Feller S., et al. Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun 7 (2000) 391-408
32. Fricke E., Keller G., Becker I., Rosivatz E., Schott C., and Plaschke S. Relationship between E-cagherin gene mutation and p53 gene mutation, p53 accumulation. Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. Int J Cancer 104 (2003) 60-65
33. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2 (2004) 371-386
34. Harms K., Nozell S., and Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61 (2004) 822-842
35. Alam T.N., O'Hare M.J., Laczko I.I., Freeman A., AI-Beith F., Masters J.R., et al. Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 52 (2004) 1083-1090
36. Schmidt D.S., Klingbeil P., Schnolzer M., and Zoller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res 297 (2004) 329-347
37. Sowter H.M., and Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 26 (2005) 1651-1656
38. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nature Med 6 (2000) 96-99
39. Barbareschi M., Pecciarini L., Cangi M.G., Maeri E., Rizzo A., Viale G., et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25 (2001) 1954-1960
40. Yousefi M., Mattu R., Gao C., and Man Y.G. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: implications for tumor progression and invasion. Appl Immunohistochem Mol Morphol 13 (2005) 30-37
41. Man Y.G., Shen T., Zhao Y.G., and Sang Q.X. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: a potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev 29 (2005) 161-169
42. Gehlsen K.R., Argraves W.S., Pierschbacher M.D., and Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 106 (1988) 925-930
43. Marshall J.F., and Hart I.R. The role of alpha v-integrins in tumor progression and metastasis. Semin Cancer Biol 7 (1996) 129-138
44. Anker P., and Stroun M. Circulating DNA in plasma or serum. Medicina (B Aires) 60 Pt 2 (2000) 699-702
45. Anker P., Lyautey J., Lederrey C., and Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta 313 1-2 (2001) 143-146
46. Anker P., and Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 15 2 (2001) 289-291
47. Anker P., Mulcahy H., and Stroun M. Circulating nucleic acidis in plasma amd serum as a noninvasive investigation for cancer: time for large-scale clinical studies?. Int J Cancer 103 2 (2003) 149-152
48. Garcia-Olmo D.C., Ruiz-Piqueras R., and Garcia-Olmo D. Circulating nucleic acidis in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 19 2 (2004) 575-583
49. Garcia-Olmo D., and Garcia-Olmo D.C. Functionality of circulating DNA: the hypothesis of genometastasis. Ann NY Acad Sci 945 (2001) 265-275
50. Anker P., Mulcahy H., Chen X.Q., and Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18 1 (1999) 65-73